28.00

8.78% 2.26

After Hours: 28.29 0.29 +1.04%

Denali Therapeutics Inc (DNLI)

Overview News Price History Option Chain Financials Why DNLI Down? Discussions Forecast

Denali Therapeutics Inc stock is traded at $28.00, with a volume of 867.08K. It is up +8.78% in the last 24 hours and up +3.40% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Previous Close:

$25.74

Open:

$25.59

24h Volume:

867.08K

Relative Volume:

0.94

Market Cap:

$4.01B

Revenue:

$340.81M

Net Income/Loss:

$-145.22M

P/E Ratio:

-25.69

EPS:

-1.09

Net Cash Flow:

$-370.93M

1W Performance:

-2.20%

1M Performance:

+3.40%

6M Performance:

+46.06%

1Y Performance:

+30.35%

1-Day Range:

$25.59

$28.07

1-Week Range:

$25.28

$28.07

52-Week Range:

$14.56

$32.13

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name

Denali Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (676)

Phone

(650) 866-8548

Address

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO

Employee

364

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

DNLI's Discussions on Twitter

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-23	Initiated	Citigroup	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Sep-06-23	Initiated	B. Riley Securities	Buy
Jan-30-23	Initiated	SVB Securities	Outperform
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy
Nov-02-22	Initiated	BofA Securities	Buy
Jun-23-22	Initiated	Berenberg	Buy
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-01-21	Initiated	SMBC Nikko	Outperform
May-18-21	Initiated	UBS	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-11-20	Reiterated	H.C. Wainwright	Buy
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-20-20	Reiterated	H.C. Wainwright	Buy
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform
Feb-28-20	Upgrade	Wedbush	Neutral → Outperform
Feb-24-20	Initiated	Jefferies	Buy
Feb-19-20	Initiated	Stifel	Hold
Jan-27-20	Upgrade	Goldman	Neutral → Buy
Sep-26-19	Initiated	Wedbush	Neutral
Sep-13-19	Initiated	Nomura	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy
Nov-15-18	Initiated	Cantor Fitzgerald	Overweight
Nov-12-18	Initiated	Janney	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Jan-02-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Initiated	Goldman	Neutral
Jan-02-18	Initiated	JP Morgan	Overweight
Jan-02-18	Initiated	Morgan Stanley	Overweight

View All

Denali Therapeutics Inc Stock (DNLI) Latest News

04:27 AM

Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.4%Still a Buy? - MarketBeat

04:27 AM

11:06 AM

Sanofi, Denali face trial setback for neuro drug (NASDAQ:DNLI) - Seeking Alpha

11:06 AM

11:00 AM

Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $28.00 at JPMorgan Chase & Co. - MarketBeat

11:00 AM

07:50 AM